Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) EPS (Basic) (2019 - 2025)

Historic EPS (Basic) for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$0.83.

  • Nurix Therapeutics' EPS (Basic) fell 1066.67% to -$0.83 in Q4 2025 from the same period last year, while for Nov 2025 it was -$3.05, marking a year-over-year decrease of 553.63%. This contributed to the annual value of -$3.05 for FY2025, which is 590.28% down from last year.
  • According to the latest figures from Q4 2025, Nurix Therapeutics' EPS (Basic) is -$0.83, which was down 1066.67% from -$1.03 recorded in Q3 2025.
  • Over the past 5 years, Nurix Therapeutics' EPS (Basic) peaked at -$0.45 during Q2 2023, and registered a low of -$1.03 during Q3 2025.
  • For the 5-year period, Nurix Therapeutics' EPS (Basic) averaged around -$0.75, with its median value being -$0.75 (2023).
  • Examining YoY changes over the last 5 years, Nurix Therapeutics' EPS (Basic) showed a top increase of 8200.0% in 2021 and a maximum decrease of 12953.96% in 2021.
  • Over the past 5 years, Nurix Therapeutics' EPS (Basic) (Quarter) stood at -$0.85 in 2021, then decreased by 1.18% to -$0.86 in 2022, then grew by 10.47% to -$0.77 in 2023, then rose by 2.6% to -$0.75 in 2024, then fell by 10.67% to -$0.83 in 2025.
  • Its EPS (Basic) stands at -$0.83 for Q4 2025, versus -$1.03 for Q3 2025 and -$0.52 for Q2 2025.